About 1,000 doses of Gilead Sciences Inc's drug lenacapavir were delivered to Zambia and Eswatini last Thursday, U.S. and ...
But the rollout is now being wielded as a political tool. What that “America First” slogan actually means for global health ...
Indian pharmaceutical giants Dr. Reddy’s Laboratories and Hetero Labs are set to disrupt HIV prevention worldwide, announcing ...
LGBTQ Nation on MSN
U.S. ships groundbreaking HIV drug to Africa, but slashed funding threatens progress
The U.S. just shipped two million doses of lenacapavir, a groundbreaking twice-a-year HIV-prevention injectable medication, ...
Merck said on Wednesday its experimental oral HIV medicine was found to be non-inferior to Gilead Sciences' top-selling drug ...
Patient advocacy groups urged the South African government to issue a compulsory license for a groundbreaking HIV prevention ...
Tatenda Makoni is a Zimbabwean-born medical student at the Medical College of Wisconsin whose work bridges global health and ...
Merck & Co. has reported another phase 3 win for islatravir in HIV, advancing its efforts to establish the near-approval ...
The United States said Tuesday it has delivered a new treatment to prevent HIV in two African countries, months after ...
Eswatini has become the first African country to receive lenacapavir, a twice-yearly HIV prevention injection that global ...
In a statement issued ahead of World AIDS Day, activists highlighted the scale of need in Africa: at least 10 million people ...
Gilead Sciences, Inc. is rated a Buy with robust profitability, solid dividend, prudent M&A and 15-20% upside potential. Read ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback